14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Tue, 7 May 2024

VVUS Predictions History

5 years ago
NameNotImportant predicted that VVUS for 2019-05-06 is going $3.80 (-4.28%)

5 years ago
NameNotImportant predicted that VVUS for 2019-05-02 is going $3.63 (-1.89%)

5 years ago
NameNotImportant predicted that VVUS for 2019-04-22 is going $3.34 (-8.49%)

5 years ago
JS predicted that VVUS for 2019-01-11 is going $3.03 (-5.90%)

5 years ago
Jeff.Kinney.97458 predicted that VVUS for 2019-01-11 is going $2.48 (-21.02%)

Rank:

5 years ago
JS predicted that VVUS for 2018-05-29 is going $0.90 (-1.97%)

6 years ago
Amar.Zulejhic.8826 predicted that VVUS for 2017-06-27 is going $1.13 (-3.42%)

Rank:

7 years ago
JS predicted that VVUS for 2017-03-13 is going $1.12 (-0.88%)

7 years ago
Jack.Cesario.Migueis.3576 predicted that VVUS for 2017-03-13 is going $1.17 (3.54%)

7 years ago
Sasha.Barnwell.180 predicted that VVUS for 2016-05-10 is going $1.29 (-1.53%)

Rank:
Click to get the best stock tips daily for free!

About VIVUS

VIVUS VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comor... VVUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT